Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8123-8135

  Gaedcke, Jochen ^a   Leha, Andreas ^a   Claus, Rainer ^b,c   Weichenhan, Dieter ^b   Jung, Klaus ^a   Kitz, Julia ^a   Grade, Marian ^a   Wolff, Hendrik A ^a   Jo, Peter ^a   Doyen, Jérôme ^d   Gérard, Jean Pierre ^d   Johnsen, Steven A ^a   Plass, Christoph ^b   Beißbarth, Tim ^a   Ghadimi, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OXALIPLATIN; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

ADAP1 GENE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BARHL2 GENE; CABLES2 GENE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; DOT1L GENE; ERAS GENE; ESRRG GENE; FEMALE; GENE; GENE CLUSTER; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECTUM CANCER; RNF220 GENE; SLC20A2 GENE; ST6GALNAC5 GENE; TAF4 GENE; DISCRIMINANT ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; GERMANY; KAPLAN MEIER METHOD; MASS SPECTROMETRY; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECTAL NEOPLASMS; REPRODUCIBILITY; RISK FACTOR; TIME; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CPG ISLANDS; DISCRIMINANT ANALYSIS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GERMANY; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84907983223     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2347     Document Type: Article

References (56)

1. Engstrom PF, Arnoletti JP, Benson AB, 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Jr., Fuchs C, Grem JL, Kiel K and Knol JA. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009; 7(8):838-881.
2. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I and Pox C. [Update S3-guideline "colorectal cancer" 2008]. Zeitschrift fur Gastroenterologie. 2008; 46(8):799-840.
3. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M and Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(28):4620-4625.
4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England journal of medicine. 2004; 351(17):1731-1740.
5. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T and Rodel C. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(16):1926-1933.
6. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J and Chau I. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). Journal of oncology: official journal of the American Society of Clinical Oncology. 2012; 30(14):1620-1627.
7. Grade M, Wolff HA, Gaedcke J and Ghadimi BM. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. 2012; 397(4):543-555.
8. Deaton AM and Bird A. CpG islands and the regulation of transcription. Genes & development. 2011; 25(10): 1010-1022.
9. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature reviews Genetics. 2012; 13(7):484-492.
10. Shen H and Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153(1):38-55.
11. Watanabe Y and Maekawa M. Methylation of DNA in cancer. Advances in clinical chemistry. 2010; 52:145-167.
12. Estecio MR and Issa JP. Dissecting DNA hypermethylation in cancer. FEBS letters. 2011; 585(13):2078-2086.
13. Gerard JP, Baulieux J, Doyen J, Gal J, Letouze E, Olschwang S, Chapet O and Romestaing P. Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique. 2012; .
14. Tan J, Yang X, Jiang X, Zhou J, Li Z, Lee PL, Li B, Robson P and Yu Q. Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer. Cell death & disease. 2014; 5:e1324.
15. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY and Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(15):1770-1776.
16. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, Brown G, McLeod R and Kennedy E. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Annals of surgical oncology. 2012; 19(7):2212-2223.
17. Dent OF, Chapuis PH, Haboubi N and Bokey L. Magnetic resonance imaging cannot predict histological tumour involvement of a circumferential surgical margin in rectal cancer. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011; 13(9):974-981.
18. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Pahlman L, Quirke P, Valentini V and van de Velde C. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(16):2142-2143.
19. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B and Walther A. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature genetics. 2010; 42(11):973-977.
20. Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, Kirac I, Tazari M, Farrington SM, Demarsh A, Zgaga L, Landry D, Benson HE, Read SH, Rudan I and Tenesa A. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. Journal of the National Cancer Institute. 2012; 104(19):1433-1457.
21. Gerard JP, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R, Barbet N, Maingon P, Mahe M, Baulieux J, Partensky C, Papillon M, Glehen O, Crozet B, Grandjean JP and Adeleine P. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(12):2404-2409.
22. Nagaraj SH and Reverter A. A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer. BMC systems biology. 2011; 5:35.
23. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD and Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012; 33(2):287-296.
24. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D and Pfeifer GP. CpG island hypermethylation in human astrocytomas. Cancer research. 2010; 70(7):2718-2727.
25. Mahmoudi T, Boj SF, Hatzis P, Li VS, Taouatas N, Vries RG, Teunissen H, Begthel H, Korving J, Mohammed S, Heck AJ and Clevers H. The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/beta-catenin coactivators essential for intestinal homeostasis. PLoS biology. 2010; 8(11):e1000539.
26. Nguyen AT and Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes & development. 2011; 25(13):1345-1358.
27. Yasuda K, Yashiro M, Sawada T, Ohira M and Hirakawa K. ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells. Anticancer research. 2007; 27(6B):4071-4075.
28. Aoyama M, Kataoka H, Kubota E, Tada T and Asai K. Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells. International journal of oncology. 2010; 37(4):1011-1016.
29. Kubota E, Kataoka H, Tanaka M, Okamoto Y, Ebi M, Hirata Y, Murakami K, Mizoshita T, Shimura T, Mori Y, Tanida S, Kamiya T, Aoyama M, Asai K and Joh T. ERas enhances resistance to CPT-11 in gastric cancer. Anticancer research. 2011; 31(10):3353-3360.
30. Matsuoka M, Sudo H, Tsuji K, Sato H, Kurita M, Suzuki H, Nishimoto I and Ogata E. ik3-2, a relative to ik3-1/Cables, is involved in both p53-mediated and p53-independent apoptotic pathways. Biochemical and biophysical research communications. 2003; 312(2):520-529.
31. Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtroder K, Sorensen KD, Laurberg S, Orntoft TF and Andersen CL. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. International journal of cancer Journal international du cancer. 2011; 129(12):2855-2866.
32. Kong Q, Zeng W, Wu J, Hu W, Li C and Mao B. RNF220, an E3 ubiquitin ligase that targets Sin3B for ubiquitination. Biochemical and biophysical research communications. 2010; 393(4):708-713.
33. Molinari C, Casadio V, Foca F, Zingaretti C, Giannini M, Avanzolini A, Lucci E, Saragoni L, Passardi A, Amadori D, Calistri D and Zoli W. Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy? Journal of cellular physiology. 2013; 228(12):2343-2349.
34. de Maat MF, van de Velde CJ, Benard A, Putter H, Morreau H, van Krieken JH, Meershoek Klein-Kranenbarg E, de Graaf EJ, Tollenaar RA and Hoon DS. Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(10):2811-2818.
35. Kohonen-Corish MR, Tseung J, Chan C, Currey N, Dent OF, Clarke S, Bokey L and Chapuis PH. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. International journal of cancer Journal international du cancer. 2014; 134(12):2820-2828.
36. Benard A, van de Velde CJ, Lessard L, Putter H, Takeshima L, Kuppen PJ and Hoon DS. Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. British journal of cancer. 2013; 109(12):3073-3083.
37. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(15):8681-8686.
38. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, Herman JG, Weijenberg MP and van Engeland M. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochimica et biophysica acta. 2012; 1825(1):77-85.
39. Claus R, Wilop S, Hielscher T, Sonnet M, Dahl E, Galm O, Jost E and Plass C. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics. 2012; 7(7).
40. Bae JM, Kim JH, Cho NY, Kim TY and Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. British journal of cancer. 2013; 109(4):1004-1012.
41. Schou JV, Larsen FO, Rasch L, Linnemann D, Langhoff J, Hogdall E, Nielsen DL, Vistisen K, Fromm A and Jensen BV. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2012; 23(10):2627-2633.
42. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC and Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. The lancet oncology. 2010; 11(3):241-248.
43. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sulberg H, Wittekind C, Potapov S, Staib L, Hess C and Weigang-Kohler K. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial. The lancet oncology. 2012; 13(7):679-687.
44. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F and Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. International journal of radiation oncology, biology, physics. 2005; 62(3):752-760.
45. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, Larson SM, Cohen AM and Guillem JG. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Annals of surgery. 2002; 236(1):75-81.
46. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R and Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(34):8688-8696.
47. Chang GJ, Rodriguez-Bigas MA, Eng C and Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009; 115(23):5432-5440.
48. Ishihara S, Watanabe T, Kiyomatsu T, Yasuda K and Nagawa H. Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer. International journal of colorectal disease. 2010; 25(12):1417-1425.
49. Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, Becker H, Ruschoff J, Hartmann A, Beissbarth T, Muller-Dornieden A, Ghadimi M, Schneider-Stock R and Gaedcke J. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery. 2012; 151(4):564-570.
50. Sonnet M, Baer C, Rehli M, Weichenhan D and Plass C. Enrichment of methylated DNA by methyl-CpG immunoprecipitation. Methods Mol Biol. 2013; 971:201-212.
51. Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, Rom J, Weichenhan D, Claus R, Rehli M, Schirmacher P, Sinn HP, Plass C and Gerhauser C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2012; 26(12):4937-4950.
52. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK and van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(44):15785-15790.
53. Kuhmann C, Weichenhan D, Rehli M, Plass C, Schmezer P and Popanda O. DNA methylation changes in cells regrowing after fractioned ionizing radiation. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2011; 101(1):116-121.
54. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A and Smyth GK. A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007; 23(20):2700-2707.
55. Tseng GC, Oh MK, Rohlin L, Liao JC and Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic acids research. 2001; 29(12):2549-2557.
56. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414): 57-74.